The Lancet Has Become a Laughing Stock

The Lancet Has Become a Laughing Stock

• On 6 May 2021 The Lancet published a blatantly flawed study of the effectiveness of the Pfizer covid vaccine on the population of Israel, claiming it was 95% effective.
• On 17 May 2021 we submitted a rapid response 250 word letter explaining why the study was flawed.
• After an initial response saying they would ask the authors for a response to our letter we heard nothing until 20 months later.
• On 8 January 2023 we got an email out of the blue from The Lancet Senior Editor Josefine Gibson apologising for never having got back to us about the letter, saying that they had asked the lead author Dr Sharon Alroy-Preis (SA-P) to respond to our letter but, because she did not provide any formal response, they have decided not to publish our letter.
• We tweeted The Lancet’s response and within 24 hours it got over one million impressions. We also published a substack article highlighting the fact we were now aware of additional problems with the paper relating to SA-P’s relationship with Pfizer.
• On 10 January 2023 we got an unsolicited email from Josefine Gibson (which we can only assume was a result of the reputation hit they got from our tweet) saying “Thank you for bringing your letter from May 2021 back to our attention. We are looking into next steps and will get back to you as soon as we can.”